The Dutch lithography giant finds itself caught between two powerful forces: a surge in artificial intelligence-related chip demand and a new US legislative push that could sever its access to the Chinese market. While ASML’s share price climbed 2% to €1,235.40 on Tuesday, extending year-to-date gains to 25% and leaving the stock just shy of its record high, the mood among investors remains cautiously optimistic at best.
Margin Pressure Creeps Into the Second Quarter
ASML’s financial performance has been a study in contrasts. The company delivered first-quarter revenue of €8.8 billion and net profit of €2.8 billion, both comfortably ahead of analyst expectations. Yet the outlook for the current quarter is less rosy. Management has guided for gross margin to slip to between 51% and 52%, down from 53% in the prior period. The market is watching closely to see whether this compression is a temporary blip or a sign of deeper structural pressure.
The regional sales mix is also shifting. South Korea now accounts for nearly half of ASML’s business, while China’s share shrank to 19% in the first quarter. That decline is partly the result of existing export restrictions, but a new threat is looming on the horizon.
The MATCH Act: A Legislative Hammer
A proposed bill in Washington, the MATCH Act, aims to cut off China’s access to older DUV lithography systems — the workhorses of legacy chip production. More aggressively, the legislation would also ban the servicing and maintenance of machines already installed in China. Without spare parts and software updates, those systems would effectively become unusable.
The stakes are high. Last year, China was ASML’s single largest market, contributing a third of total revenue. Management had already penciled in a decline to around 20% by 2026 under existing sanctions. The MATCH Act, if passed, could push that figure even lower. JPMorgan estimates that a full implementation could shave up to 10% off ASML’s earnings, with sales to other regions unlikely to fully compensate for the loss.
Should investors sell immediately? Or is it worth buying Asml?
The bill still needs to clear both chambers of Congress and receive the president’s signature. It includes a 150-day grace period for allied nations like the Netherlands to tighten their own export controls before Washington acts unilaterally.
Dividends and Buybacks Keep Shareholders Happy
Against this uncertain backdrop, ASML continues to reward its shareholders generously. The company’s shares traded ex-dividend on April 24, with the annual general meeting approving a final payout of €2.70 per share. Combined with interim dividends, total distributions for the last financial year amount to €7.50 per share — a 17% increase year-on-year.
The capital return program extends beyond dividends. ASML has a €12 billion share buyback scheme running through 2028, and in the first quarter alone it repurchased €1.1 billion worth of its own stock. The previous quarter saw buybacks exceeding €1 billion as well.
AI-Driven Demand Offsets Some Risk
The fundamental picture remains robust. ASML is benefiting from insatiable demand for AI chips, which is driving a shift toward its more expensive EUV lithography systems. The company plans to ramp up production capacity for these machines significantly by 2027. Memory chip manufacturers are already reporting sold-out capacity for the current year.
ASML has raised its full-year revenue guidance to between €36 billion and €40 billion, reflecting the strength of its order book. For now, that backlog provides a buffer against the political headwinds. But the trajectory of the stock will ultimately hinge on two unknowns: whether the MATCH Act becomes law, and whether the margin dip in the current quarter proves to be a one-off or the start of a longer-term trend.
Ad
Asml Stock: Buy or Sell?! New Asml Analysis from April 24 delivers the answer:
The latest Asml figures speak for themselves: Urgent action needed for Asml investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 24.
Asml: Buy or sell? Read more here...
